213 related articles for article (PubMed ID: 24853187)
1. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
Yang X; Yang P; Shen J; Osaka E; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Br J Cancer; 2014 Jun; 110(12):2896-904. PubMed ID: 24853187
[TBL] [Abstract][Full Text] [Related]
2. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
[TBL] [Abstract][Full Text] [Related]
3. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.
Duan Z; Choy E; Hornicek FJ
PLoS One; 2009 Oct; 4(10):e7415. PubMed ID: 19823672
[TBL] [Abstract][Full Text] [Related]
4. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
[TBL] [Abstract][Full Text] [Related]
5. Tetrandrine prevents multidrug resistance in the osteosarcoma cell line, U-2OS, by preventing Pgp overexpression through the inhibition of NF-κB signaling.
Lu Y; Li F; Xu T; Sun J
Int J Mol Med; 2017 Apr; 39(4):993-1000. PubMed ID: 28260091
[TBL] [Abstract][Full Text] [Related]
6. A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Duan Z; Zhang J; Ye S; Shen J; Choy E; Cote G; Harmon D; Mankin H; Hua Y; Zhang Y; Gray NS; Hornicek FJ
BMC Cancer; 2014 Sep; 14():681. PubMed ID: 25236161
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.
Duan Z; Li X; Huang H; Yuan W; Zheng SL; Liu X; Zhang Z; Choy E; Harmon D; Mankin H; Hornicek F
J Med Chem; 2012 Apr; 55(7):3113-21. PubMed ID: 22400811
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.
Patel NR; Rathi A; Mongayt D; Torchilin VP
Int J Pharm; 2011 Sep; 416(1):296-9. PubMed ID: 21703341
[TBL] [Abstract][Full Text] [Related]
9. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
10. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.
Cagliero E; Ferracini R; Morello E; Scotlandi K; Manara MC; Buracco P; Comandone A; Baroetto Parisi R; Baldini N
Oncol Rep; 2004 Nov; 12(5):1023-31. PubMed ID: 15492788
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
Duan Z; Lamendola DE; Penson RT; Kronish KM; Seiden MV
Cytokine; 2002 Mar; 17(5):234-42. PubMed ID: 12027404
[TBL] [Abstract][Full Text] [Related]
12. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
14. NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.
Ye S; Zhang J; Shen J; Gao Y; Li Y; Choy E; Cote G; Harmon D; Mankin H; Gray NS; Hornicek FJ; Duan Z
Br J Pharmacol; 2016 Feb; 173(3):613-26. PubMed ID: 26603906
[TBL] [Abstract][Full Text] [Related]
15. Effects of Kampo medicines on MDR-1-mediated multidrug resistance in human hepatocellular carcinoma HuH-7/PTX cells.
Hyuga S; Shiraishi M; Hori A; Hyuga M; Hanawa T
Biol Pharm Bull; 2012; 35(10):1729-39. PubMed ID: 23037162
[TBL] [Abstract][Full Text] [Related]
16. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
[TBL] [Abstract][Full Text] [Related]
17. Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function.
Elamanchili P; McEachern C; Burt H
J Pharm Sci; 2009 Mar; 98(3):945-58. PubMed ID: 18623213
[TBL] [Abstract][Full Text] [Related]
18. Folic Acid-Modified Nanoerythrocyte for Codelivery of Paclitaxel and Tariquidar to Overcome Breast Cancer Multidrug Resistance.
Zhong P; Chen X; Guo R; Chen X; Chen Z; Wei C; Li Y; Wang W; Zhou Y; Qin L
Mol Pharm; 2020 Apr; 17(4):1114-1126. PubMed ID: 32176509
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
20. Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Hill BT; Whelan RD; Shellard SA; McClean S; Hosking LK
Invest New Drugs; 1994; 12(3):169-82. PubMed ID: 7896535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]